Delivery Order SPE2DB22D3501-SPE2DB25FVZ06
- Not listed
- The Defense Logistics Agency awarded a $14.5K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ENBREL 25 mg/0.5 ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency has awarded a delivery order valued at $8,576.63 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support...
- The Defense Logistics Agency awarded a $19,183.16 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, effective June 2, 2025, with completion targeted for June 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $18,364.76 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/ml syringes. This firm fixed price contract, awarded on June 17, 2025, with an ultimate completion date of June 18, 2025, represents a competitively awarded non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite...
- The Defense Logistics Agency awarded a $22,897 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes, with performance in Conshohocken, Pennsylvania and an ultimate completion date of June 2, 2025. This is a non-set-aside, competitively awarded contract that reflects AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's military and veteran healthcare systems. The award represents a child order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes valued at $68,950.48 on September 12, 2025, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling and extends through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Enbrel 50 mg/mL syringes with a ceiling value of $13,602.12. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The performance location is the company's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $31,043.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 5, 2025. This non-set-aside award was made competitively and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion vehicle running through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for ENBREL 50 mg/ml syringes valued at $29,284.84. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania facility with...
- The Defense Logistics Agency awarded a $22,930.62 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes. The contract, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor supporting federal medical procurement needs, particularly for military and...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FVZ06Delivery Order
The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of June 10, 2025. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to military and veteran healthcare systems. Enbrel is a biologic medication used primarily for treating autoimmune conditions such as rheumatoid arthritis, and this delivery order fulfills the Defense Health Agency's medical supply requirements. The award reflects AmerisourceBergen's established capability to deliver specialty pharmaceutical products through the DLA's global pharmaceutical support vehicle, which enables the company to serve military healthcare programs and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.3k | 6/9/25 |